- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01591889
Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed Conditions
January 19, 2018 updated by: Roxane Laboratories
A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed Conditions
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Tinidazole 500 mg Tablet under fed conditions.
Study Overview
Study Type
Interventional
Enrollment (Actual)
28
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77042
- Novum Pharmaceutical Research Services
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening
Exclusion Criteria:
- Positive test for HIV, Hepatitis B, or Hepatitis C.
- Treatment with known enzyme altering drugs.
- History of allergic or adverse response to tinidazole or any comparable or similar product.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: tindamax
500 mg tablet
|
500 mg tablet
Other Names:
|
Active Comparator: tinidazole
500 mg tablet
|
500 mg tablet
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
bioequivalence determined by statistical comparison Cmax
Time Frame: 8 days
|
8 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Soran Hong, MD, Novum Pharmaceutical Research Services
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2009
Primary Completion (Actual)
September 1, 2009
Study Completion (Actual)
September 1, 2009
Study Registration Dates
First Submitted
May 1, 2012
First Submitted That Met QC Criteria
May 3, 2012
First Posted (Estimate)
May 4, 2012
Study Record Updates
Last Update Posted (Actual)
January 23, 2018
Last Update Submitted That Met QC Criteria
January 19, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TINI-T500-PVFD-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Trichomoniasis
-
University of Alabama at BirminghamNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
University of PittsburghCompletedBacterial Vaginosis | Vulvovaginal Candidiasis | TrichomoniasisUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedCandidiasis | Bacterial Vaginosis | TrichomoniasisUnited States, Kenya
-
National Institute of Allergy and Infectious Diseases...CompletedGonococcal Infection | Trichomoniasis | Chlamydial InfectionUnited States
-
National Institute of Allergy and Infectious Diseases...TerminatedGonorrhoea | Trichomoniasis | Chlamydial InfectionUnited States
-
Visby MedicalCompletedGonococcal Infection | Trichomoniasis | Chlamydial InfectionUnited States
-
Richard CrosbyNational Institute of Mental Health (NIMH)CompletedHIV Infections | Chlamydia | Gonorrhea | Syphilis | TrichomoniasisUnited States
-
London School of Hygiene and Tropical MedicineBiomedical Research and Training InstituteActive, not recruitingHIV Infections | Sexually Transmitted Diseases | Hepatitis B | Pregnancy | Chlamydia | Gonorrhea | Syphilis | Sexually Transmitted Infection | TrichomoniasisZimbabwe
Clinical Trials on Tinidazole
-
Shangrong FanNot yet recruitingTrichomonas VaginitisChina
-
University of Campinas, BrazilUnknown
-
Kaiser PermanenteWithdrawnRecurrent Bacterial VaginosisUnited States
-
University of PittsburghMission PharmacalCompleted
-
University of Alabama at BirminghamNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Tongji HospitalShanghai Children's HospitalCompletedTreatment Compliance | Cholangitis, Secondary Biliary | Antibodies Drug SpecificChina
-
Sheba Medical CenterUnknownAbdominal Pain | Chronic Diarrhea | BloatingIsrael
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaCompletedHelicobacter Pylori InfectionItaly
-
Shandong UniversityRecruitingHelicobacter Pylori InfectionChina
-
Fu Xing Hospital, Capital Medical UniversityCompletedChronic EndometritisChina